• Written informed consent obtained from the subject prior to performing any protocol- related procedures, including screening evaluations

• Histological or cytological diagnosis of NSCLC

• Stage I-IIA tumours ≤ 5 cm

• Peripheral tumours

• Medically inoperable patients or patients refusing surgery

• Received no prior chemotherapy or radiation therapy for NSCLC

• Age \> 18 years at time of study entry, no upper age limit

• WHO performance status 0-2

• Adequate normal organ and marrow function as defined below:

• Haemoglobin ≥ 9.0 g/dL

• Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (\> 1500 per mm3)

• Platelet count ≥ 100 x 109/L (\>100,000 per mm3)

• Serum bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)

• AST/ALT ≤ 2.5 x institutional upper limit of normal

• Serum creatinine CL\>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by chrome-EDTA or Iohexol clearance

• Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal subjects

• Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up